ERBB2 and breast cancer: Immunohistochemical data revealed that among 263 BC patients, 64.3% expressed estrogen receptor (ER+), 52.9% progesterone receptor (PR+) and 35.7% overexpressing HER2 (HER2+) (Table 2).